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TO THE EDITOR
Chronic idiopathic/spontaneous urticaria
(CIU/CSU), which affects B1% of the
United States population, is defined as
recurrent hives for 46 weeks (Kaplan
and Greaves, 2009). Active CIU/CSU
patients uniquely display suppressed
basophil FceRI-mediated histamine
release (BHR) (Saini, 2014). This is a fea-
ture that improves in disease remission
(Kern and Lichtenstein, 1976; Eckman
et al., 2008; Oliver et al., 2015). The
pathways leading to basophil FceRI
suppression in CIU/CSU are unclear.
There is evidence that IgE has a role in
urticaria. For example, injection of cold
urticaria patients’ serum into a healthy
subject’s skin transfers the sensitivity to
the cold stimulus (Gruber et al., 1988).
Clinical trials with monoclonal anti-IgE
(omalizumab) in subjects with CIU/CSU
have shown rapid symptom relief,
which implicates IgE in the disease path-
way (Gober et al., 2008; Saini et al.,
2011; Maurer et al., 2013). Furthermore,
the autoimmune theory of CIU/CSU
pathogenesis proposes that serum IgG
autoantibodies specific to IgE or the
IgE receptor directly activate skin mast
cells and basophils in a subset of CIU/
CSU subjects (Kaplan and Greaves,
2009). In this study, we examined the
ability of active CIU/CSU patients’
serum to transfer FceRI-mediated
BHR suppression to healthy baso-
phils and further test the contributions
of IgE, IgG, and complement in
the observed basophil mediator sup-
pression.
Healthy adults (n¼8, 25% female)
had repeated blood collections using
an institutional review board approved
protocol. CIU/CSU sera were collected
as part of a longitudinal study (Baker
et al., 2008). Written informed consent
was obtained from all subjects, whether
for blood or for sera. Remission sera
were collected from CIU/CSU patients
with no skin symptoms or medication
use for X2 months (Baker et al., 2008).
For CIU/CSU patients using omali-
zumab, sera collection occurred before
and after the patient had been on
therapy for 1 to 4 months with marked
clinical improvement (Gober et al.,
2008). All serum samples were stored
at 20 1C.
Basophils were purified from venous
blood using percoll density gradients
(GE Healthcare, Uppsala, Sweden) that
were followed by negative selection as
described (Vonakis et al., 2007). Purified
basophils (4200,000 basophils per
condition) were cultured overnight
(37 1C, 18–22 h, 5% CO2) in Iscove’s
Modified Dulbecco’s Media media
(Gibco, New York, NY) ±15% serum
v/v (chosen because 15% does not
induce BHR; Vasagar et al., 2006).
Each culture experiment utilized a
single individual’s serum (CIU/CSU
or autologous). IL-3 (0.1–100 ng ml1;
R&D Systems, Minneapolis, MN) was
added for basophil survival, with no
difference observed in results based on
the concentration of IL-3. Post-culture
analysis of the histamine content of
media supernatants and total basophil
histamine content revealed no
differences between conditions.
After culture, cells were collected,
stimulated with polyclonal goat
anti-human IgE (0.01–1mg ml 1) or for-
mylmethionine-leucyl-phenylalanine
(fMLP-N, 106 M; Sigma-Aldrich, Mis-
souri, St Louis, MO) at 410,000 baso-
phils per stimulation, and assayed for
histamine by fluorimetry (Vonakis et al.,
2007). In select experiments, CIU/CSU
serum was tested as follows: (i) paired
sera from patients before and after
remission, (ii) serum depleted of IgE by
overnight incubation with omalizumab
covalently coupled to Sepharose-CL-4B
as previously validated to achieve a
98% IgE depletion rate (Eckman et al.,
2008), (iii) serum heat inactivated at
56 1C for 30 min to denature IgE and
inactivate complement (Ishizaka et al.,
1986), and (iv) serum IgG depleted by
adsorption with Staphylococcal Protein
G Sepharose 4B-CL (Fu et al., 2007;
493% depletion).
All statistics were performed with
Prism 4.0 using the Wilcoxon signed-
rank test between the two groups being
compared at the same concentration of
stimulant. Error bars in the graphs indi-
cate the standard error of the mean
(SEM).
Healthy donor basophils cultured
in active CIU/CSU subjects’ serum
exhibited marked suppression of FceRI-
mediated BHR when compared with
media (Figure 1a) or media with
autologous serum (Supplementary
Figure S1a online). In contrast, basophils
cultured in media or autologous serum
showed no significant difference in
subsequent BHR (Supplementary Figure
S1b online). Further, fMLP-N-induced
BHR did not differ between the media
versus CIU/CSU serum or autologous
serum versus CIU/CSU serum cultures
(data not shown).
In remission, CIU/CSU patients show
an increase in their basophil HR profile
(Eckman et al., 2008). Therefore, we
compared the effect of serum cultureAccepted article preview online 3 February 2015; published online 5 February 2015
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from CIU/CSU patients during active
disease and in remission. Basophils
cultured in remission serum displayed
significantly less BHR suppression
compared with active serum culture
and were similar to culture in media
alone (Figure 1b).
Given that omalizumab therapy
rapidly reduces symptoms in CIU/CSU
patients (Gober et al., 2008; Saini et al.,
2011; Maurer et al., 2013), we explored
the role of IgE in conveying BHR
suppression. IgE depletion by immuno-
adsorption failed to change the degree
of BHR suppression obtained with intact
serum (Figure 2a). Similarly, the use of
heat-inactivated serum, inactivating IgE
and complement, also did not alter BHR
suppression after culture (Figure 2b).
Serum from patients with CIU/CSU
disease before and after clinical
improvement on omalizumab therapy
(Figure 2c) did not differ in their capa-
city to transfer BHR suppression.
Likewise, basophils cultured in IgG-
depleted CIU/CSU serum showed simi-
lar suppression of BHR to sham-
depleted serum (Figure 2d).
An unclear mechanism suppresses the
FceRI pathway of blood basophils in
subjects with active CIU/CSU. We have
reported altered expression of inhibitory
molecules in the IgE receptor signaling
pathway (Vonakis et al., 2007). In
remission, basophil FceRI histamine res-
ponse increases toward a more normal
profile (Eckman et al., 2008). To gain
insights into factors responsible for baso-
phil FceRI suppression, we examined
the effects of culture of healthy donor
basophils with well-characterized
CIU/CSU patients’ serum. We consi-
stently observed marked suppression of
FceRI-mediated BHR in cultures using
active CIU/CSU patients’ serum but
found that the serum from patients in
remission had less capacity to suppress
basophil HR.
Given the putative roles of IgE in CIU/
CSU in disease, IgE depletion and heat
denaturation of serum from active CIU/
CSU patients were examined for its’
impact on the suppression of donor
BHR. Such approaches failed to alter
the ability of these sera to suppress
basophil mediator release. Omalizumab
therapy led to rapid symptom relief in
CIU/CSU subjects with symptom
rebound when therapy was discontinued
(Maurer et al., 2013). However, culture
with CIU/CSU serum in the pre-
sence of therapeutic levels of omali-
zumab also failed to impair the transfer
of BHR suppression. These observations
suggest that the suppressive factor in
the serum of CIU/CSU patients acts
through the IgE receptor pathway but is
not IgE. Furthermore, IgG depletion of
active CIU/CSU serum also failed to alter
the transfer of mediator suppression,
indicating that IgG antibodies are not
directly involved in the phenomenon.
Although the nature of the serum
factor responsible for suppressing BHR
in CIU/CSU remains unknown, its sig-
nificance as a potential disease biomar-
ker for CIU/CSU is apparent, but more
work is needed. The suppression factor
is present in active disease, reduced as
the patient experiences natural disease
remission, and is independent of IgE and
IgG antibodies. Elucidation of the nature
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Figure 1. Normal basophils cultured in individual chronic idiopathic/spontaneous urticaria (CIU/CSU)
serum show a suppressed basophil histamine release (BHR) profile that reverses in disease remission
serum. Purified basophils from healthy donors were cultured overnight in media or CIU/CSU serum and
assessed for FceRI-mediated BHR. (a) CIU/CSU serum–cultured basophils showed significant BHR
suppression as compared with parallel media–cultured basophils (n¼35; **Po0.0001 to matched
control). (b) Basophils cultured in CIU/CSU patients’ serum obtained during active disease showed marked
BHR suppression relative to culture in the same subject’s serum during remission (n¼ 8). No statistical
differences were observed between the levels of BHR from cells cultured in serum from CIU/CSU patients
in remission or media alone. All media versus active serum statistics were þ Po0.05, whereas all
remission versus active serum statistics were *Po0.01.
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Figure 2. The source of the suppressive factor is not complement, IgE, or IgG autoantibody. FceRI-
mediated basophil histamine release (BHR) suppression does not appear to be affected by (a) serum IgE
depletion by immunoadsorption (n¼ 4) or (b) heat inactivation of IgE and complement (n¼3). The three
sera used in a contained 33, 212, and 355 ng ml 1 of IgE, and after immunoadsorption, levels were
reduced to 2% of original values. (c) Serum from patients pre and post omalizumab therapy (n¼ 6) showed
no differences in the degree of histamine suppression observed. (d) IgG was depleted from active CIU/CSU
serum using protein G Sepharose and evaluated in comparison to the untreated serum for BHR suppression
(n¼ 3). No statistical differences were seen among the active, IgG-depleted, or sham-depleted sera.
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of this factor may provide insights into
the pathogenesis of CIU/CSU.
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Loss of Primary Cilia in Melanoma Cells Is Likely
Independent of Proliferation and Cell Cycle Progression
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TO THE EDITOR
Accurate diagnosis of melanoma is valu-
able in reducing melanoma mortality
and morbidity. A number of candidate
biomarkers have been developed for
melanoma (Mandala and Massi, 2014);
however, none has been accepted as
being accurate, easily interpretable, and
practical in diagnosing histologi-
cally challenging melanocytic lesions.
Recently, it was found that primary cilia
exist in melanocytes and melanoma
cells and that primary cilia were fre-
quently lost in melanomas (Kim et al.,
2011; Le Coz et al., 2014), suggesting
that the primary cilium may be used as a
biomarker for melanoma. However, it
remained unclear whether the loss of
cilia in melanoma was due to increased
proliferation or cell cycle progression.
The statistical power of using primary
cilium as a biomarker also remained to
be established.
Here, we independently evaluated
primary cilia by immunofluorescence
microscopy on 87 cases of melanocytic
nevi and melanomas obtained from the
archival collections of the Department
of Pathology of Stony Brook Medicine
between 2003 and 2011. This study was
approved by the IRB of Stony Brook
University. ARL13B (Proteintech, Chicago,
IL), acetylated a-tubulin (Sigma, St. Louis,
MO), and ACIII (Santa Cruz Biotechnol-
ogy, Dallas, TX) were used to detect
primary cilia; gamma-tubulin and chibby
(CBY1, (Takemaru et al., 2003)) were used
to detect basal body; SOX10 (Santa Cruz
Biotechnology) and S100 (BioCare
Medical, Concord, CA) were used to
detect melanocytes and melanoma cells,
as described previously (Dai et al., 2011).
Comparable results were obtained from all
antibodies of each category (Supple-
mentary Figure S1 and S2 online). An
average of 366 (97–959) cells were eval-
uated for each specimen.
Remarkable decrease in ciliated cells
was found in all types of melanoma
when compared with nevi. Specifically,
24.85±6.33% of melanocytes in nevi
were ciliated (Figure 1a). In contrast,
percentages of ciliated cells were reduced
to 4.36±2.13, 2.85±2.43, and 1.16±
0.70% in melanoma in situ, primary
melanoma, and metastatic melanoma,
respectively (Figure 1b–d). The decrease
was statistically significant (P¼ 2.50
10 17 by two-way analysis of variance;
Figure 1e). In comparison with nevi, all
types of melanoma demonstrated a
highly significant reduction in ciliated
cells (Po1109 by the Tukey test).
Proliferating cells typically show
higher rates of cilia formation comparedAccepted article preview online 28 January 2015; published online 26 February 2015
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